The Academic
International Journal of Multidisciplinary Research

An Online Peer Reviewed / Refereed Journal
Volume 3 | Issue 5 | May 2025
ISSN: 2583-973X (Online)
Website: www.theacademic.in

Comprehensive Pathological Insights into Triple-Negative Breast Carcinoma

Dr. Minhaj Fatima

Department of Pathology, Surabhi Institute of Medical Sciences, Telangana, India

Dr. Tehreem Qureshi

Department of Pathology, Surabhi Institute of Medical Sciences, Telangana, India

ARTICLE DETAILS

Research Paper

Accepted: 26-05-2025

Published: 10-06-2025

Keywords:

Triple-negative breast carcinoma, pathology, molecular subtypes, immunohistochemistry, basal-like carcinoma, prognosis, BRCA, PD-L1, tumor microenvironment

ABSTRACT

Triple-negative breast carcinoma (TNBC) is a distinct and clinically challenging subtype of breast cancer defined by the absence of estrogen receptor (ER), progesterone receptor (PR), and HER2/neu expression. Representing approximately 15–20% of all breast cancers, TNBC is associated with a more aggressive clinical course, higher recurrence rates, and poorer overall survival compared to other molecular subtypes. Its lack of therapeutic targets limits treatment options, rendering systemic chemotherapy the mainstay of management. From a pathological perspective, TNBC displays a wide histological spectrum, including high-grade invasive ductal carcinoma of no special type, as well as rarer variants such as metaplastic, apocrine, and medullary-like carcinomas. Immunohistochemistry plays a crucial role in diagnosis and subclassification, with additional markers like Ki-67, cytokeratin 5/6, EGFR, and p53 often aiding in characterization. Recent advances in genomic profiling have revealed a high degree of molecular heterogeneity within TNBC, leading to the identification of distinct subtypes such as basal-like, immunomodulatory, mesenchymal, and luminal androgen receptor-positive tumors. These subtypes have implications for prognosis and emerging targeted therapies. BRCA1/2 mutations, PD-L1 expression, and tumor-infiltrating lymphocytes (TILs) are key biomarkers guiding treatment decisions, particularly in the context of PARP inhibitors and immunotherapy. This review provides a comprehensive overview of the pathological features, diagnostic strategies, and molecular underpinnings of TNBC, emphasizing the role of the pathologist in navigating its complexity. As precision oncology evolves, integrating conventional histopathology with molecular diagnostics will be

essential for improving therapeutic outcomes in patients with TNBC.

DOI : https://doi.org/10.5281/zenodo.15651318

1. Introduction

Breast cancer is the most common malignancy among women globally, with an increasing incidence and significant mortality, especially in low- and middle-income countries. While most breast cancers express hormone receptors or HER2, a clinically significant subset—termed triple-negative breast carcinoma (TNBC)—lacks these markers, rendering traditional endocrine or anti-HER2 therapies ineffective.

TNBC is not a single disease entity but a constellation of heterogeneous tumors that share a common immunohistochemical profile but diverge in morphology, molecular characteristics, and behavior. Understanding the pathology of TNBC is essential to improve diagnostic accuracy, predict outcomes, and guide therapeutic decisions.

2. Epidemiology and Risk Factors

TNBC disproportionately affects certain populations. It is more prevalent among:

- **Younger women** (under 50 years)
- **African-American women**, who often present with more aggressive disease
- **BRCA1 mutation carriers**, especially those with hereditary breast and ovarian cancer syndrome
- Women with **obesity, high parity**, and **shorter duration of breastfeeding**

In India and other developing regions, TNBC may constitute up to 30% of breast cancer cases, possibly due to genetic, environmental, and reproductive factors. This highlights the need for region-specific strategies for early detection and management.

3. Histopathological Features

TNBC most commonly presents as **invasive ductal carcinoma of no special type (IDC-NST)**, with hallmark features including:

- High nuclear grade (Grade III)
- High mitotic count
- Geographic or central necrosis
- Pushing rather than infiltrative margins

- Stromal lymphocytic infiltration (in some subtypes)

Morphological Variants

Several rare but clinically relevant histologic subtypes fall within the TNBC category:

- **Metaplastic carcinoma**: Exhibits heterologous elements (e.g., chondroid, osseous) or epithelial-mesenchymal transition. Typically triple-negative with poor response to conventional therapy.
- **Medullary carcinoma-like features**: Syncytial growth pattern with high-grade nuclei and dense lymphoid stroma. Despite aggressive histology, it may have a relatively favorable prognosis.
- **Apocrine carcinoma**: Displays abundant eosinophilic cytoplasm and apical snouts. Frequently AR-positive, suggesting a potential therapeutic target.
- **Adenoid cystic and secretory carcinomas**: Though triple-negative, these subtypes generally have a slow-growing, indolent course with distinct genetic alterations (e.g., ETV6-NTRK3 fusion in secretory carcinoma).

The morphological heterogeneity reflects the diverse biological behavior of TNBC and mandates careful histopathological examination.

4. Immunohistochemistry and Diagnostic Workup

The immunohistochemical (IHC) diagnosis of TNBC hinges on three negative markers:

- **Estrogen receptor (ER)**: <1% nuclear staining
- **Progesterone receptor (PR)**: <1% nuclear staining
- **HER2**: IHC 0–1+ or IHC 2+ with negative FISH/CISH

Additional IHC markers are useful in subtyping and differential diagnosis:

- **Cytokeratin 5/6, CK14, and EGFR**: Positivity suggests basal-like phenotype
- **p53**: Aberrant expression (either null or overexpression) in ~80% of cases
- **Ki-67**: High proliferative index (>30–40%)
- **Androgen Receptor (AR)**: Positive in 10–15% of TNBCs; defines luminal AR subtype
- **GATA3**: Often retained, aiding in identifying breast origin in metastatic settings

The immunophenotype should be correlated with morphology and clinical context to avoid misclassification, especially in metaplastic or poorly differentiated tumors.

5. Molecular Classification

TNBC is molecularly heterogeneous. Gene expression profiling (e.g., microarray or RNA-sequencing) has led to classification into multiple subtypes:

Lehmann's Six Subtypes (2011, revised 2016):

1. **Basal-like 1 (BL1)**: Enriched for DNA damage response genes; high proliferation; responsive to platinum agents
2. **Basal-like 2 (BL2)**: Growth factor signaling; relatively chemo-resistant
3. **Immunomodulatory (IM)**: Immune cell signaling; may respond to immunotherapy
4. **Mesenchymal (M)**: EMT features, angiogenesis pathways
5. **Mesenchymal stem-like (MSL)**: Similar to M, with reduced proliferation
6. **Luminal androgen receptor (LAR)**: Driven by AR signaling; potential for AR-targeted therapy

PAM50 Classification:

Most TNBCs fall under the **basal-like intrinsic subtype** (~80%), but not all basal-like tumors are triple-negative.

Genomic Alterations:

- **TP53 mutations**: Found in over 80% of TNBCs
- **PIK3CA mutations**: Common in LAR subtype
- **BRCA1/2 mutations**: Especially BRCA1; associated with homologous recombination deficiency (HRD)

These molecular profiles offer potential targets for therapy and help stratify patients in clinical trials.

6. Prognostic Factors in TNBC

Compared to other breast cancer subtypes, TNBC is associated with:

- **Higher recurrence rates**, particularly in the first 3 years post-diagnosis
- **Increased visceral and brain metastasis**
- **Shorter overall and disease-free survival**

However, TNBC also tends to exhibit **better initial responses to neoadjuvant chemotherapy**, particularly anthracycline- and taxane-based regimens. **Pathologic complete response (pCR)** is a strong favorable prognostic indicator.

Favorable Prognostic Indicators:

- High TILs (tumor-infiltrating lymphocytes)
- Achieving pCR after neoadjuvant chemotherapy
- BRCA1 mutation (due to platinum sensitivity)

Unfavorable Prognostic Indicators:

- Large tumor size and nodal involvement
- Low TILs
- Residual disease after neoadjuvant therapy
- Specific histologic variants (e.g., metaplastic carcinoma)

7. Role of BRCA Mutations and Homologous Recombination Deficiency

Approximately 15–20% of TNBCs harbor **germline BRCA1/2 mutations**, which confer susceptibility to DNA-damaging agents like platinum drugs and **PARP inhibitors** (e.g., olaparib, talazoparib).

BRCA1-mutated tumors often display:

- Basal-like histology
- High-grade features
- Genomic instability

The identification of BRCA status is now standard in TNBC diagnosis and treatment planning.

8. Tumor Microenvironment and Immune Markers

The immune microenvironment in TNBC plays a crucial prognostic and therapeutic role.

- **TILs**: High levels are associated with better prognosis and pCR rates.
- **PD-L1 expression**: Found in 20–30% of TNBCs. Its presence in tumor or immune cells predicts benefit from immune checkpoint inhibitors (e.g., atezolizumab, pembrolizumab).
- **Immune gene signatures**: Under investigation to predict response to immunotherapy.

Standardized assessment of TILs and PD-L1 is increasingly being incorporated into routine pathology practice.

9. Emerging Biomarkers and Techniques

Advances in molecular pathology have introduced novel biomarkers and technologies:

- **Next-Generation Sequencing (NGS)**: Enables broad genomic profiling for targeted therapies
- **Liquid biopsy (ctDNA)**: Non-invasive method for monitoring treatment response and detecting minimal residual disease
- **Multiplex IHC and spatial transcriptomics**: Allow high-resolution analysis of tumor-immune interactions
- **Artificial Intelligence (AI) in histopathology**: Promising for automated grading and biomarker quantification

While not yet routine, these tools are revolutionizing breast cancer pathology.

10. Diagnostic Challenges and Differential Diagnosis

Given its varied histological patterns, TNBC must be distinguished from:

- **High-grade serous carcinoma of the ovary**: May also be triple-negative; WT1 and PAX8 help differentiate
- **Lymphoma**: Especially in medullary-like tumors; CD45 is diagnostic
- **Metastases from other primaries**: GATA3 and mammaglobin help confirm breast origin

Accurate diagnosis requires a combination of morphology, IHC, and clinical correlation.

11. Therapeutic Implications of Pathology

The pathological features of TNBC directly influence therapeutic strategies:

- **Chemotherapy**: Remains the cornerstone; platinum-based regimens used in BRCA-mutated or basal-like TNBC
- **PARP inhibitors**: Effective in BRCA-mutated cases
- **Immunotherapy**: PD-L1-positive tumors benefit from checkpoint blockade
- **AR inhibitors (e.g., enzalutamide)**: Under investigation for LAR subtype
- **PI3K/AKT/mTOR inhibitors**: Targeting aberrant signaling pathways

Pathologists play a critical role in identifying biomarkers that guide these treatments.

12. Conclusion

Triple-negative breast carcinoma presents a diagnostic and therapeutic challenge due to its biological complexity, morphological diversity, and lack of targeted treatment options. A robust pathological

evaluation—encompassing histology, immunophenotyping, and molecular profiling—is pivotal in characterizing this aggressive cancer. With advances in precision oncology, the pathologist's role extends beyond diagnosis to prognostication and treatment planning. Integrating traditional histopathology with molecular diagnostics will be key to improving outcomes in TNBC patients worldwide.

References:

- Bianchini, G., Balko, J. M., Mayer, I. A., Sanders, M. E., & Gianni, L. (2016). Triple-negative breast cancer: Challenges and opportunities of a heterogeneous disease. *Nature Reviews Clinical Oncology, 13*(11), 674–690. https://doi.org/10.1038/nrclinonc.2016.66

- Dent, R., Trudeau, M., Pritchard, K. I., Hanna, W. M., Kahn, H. K., Sawka, C. A., ... & Andrulis, I. L. (2007). Triple-negative breast cancer: Clinical features and patterns of recurrence. *Clinical Cancer Research, 13*(15), 4429–4434. https://doi.org/10.1158/1078-0432.CCR-06-3045

- Foulkes, W. D., Smith, I. E., & Reis-Filho, J. S. (2010). Triple-negative breast cancer. *The New England Journal of Medicine, 363*(20), 1938–1948. https://doi.org/10.1056/NEJMra1001389

- Rakha, E. A., Reis-Filho, J. S., & Ellis, I. O. (2008). Basal-like breast cancer: A critical review. *Journal of Clinical Oncology, 26*(15), 2568–2581. https://doi.org/10.1200/JCO.2007.13.1748

- Lehmann, B. D., Bauer, J. A., Chen, X., Sanders, M. E., Chakravarthy, A. B., Shyr, Y., & Pietenpol, J. A. (2011). Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. *The Journal of Clinical Investigation, 121*(7), 2750–2767. https://doi.org/10.1172/JCI45014